Display options
Cite
Largeron N, Lévy P, Wasem J, et al. Role of vaccination in the sustainability of healthcare systems. J Mark Access Health Policy. 2015;3doi: 10.3402/jmahp.v3.27043.
Largeron, N., Lévy, P., Wasem, J., & Bresse, X. (2015). Role of vaccination in the sustainability of healthcare systems. Journal of market access & health policy, 3. https://doi.org/10.3402/jmahp.v3.27043
Largeron, Nathalie, et al. "Role of vaccination in the sustainability of healthcare systems." Journal of market access & health policy vol. 3 (2015). doi: https://doi.org/10.3402/jmahp.v3.27043
Largeron N, Lévy P, Wasem J, Bresse X. Role of vaccination in the sustainability of healthcare systems. J Mark Access Health Policy. 2015 Aug 12;3. doi: 10.3402/jmahp.v3.27043. eCollection 2015. PMID: 27123188; PMCID: PMC4802702.
Copy Download .nbib Format: NLM
Share it on

J Mark Access Health Policy. 2015 Aug 12;3. doi: 10.3402/jmahp.v3.27043. eCollection 2015.

Role of vaccination in the sustainability of healthcare systems.

Journal of market access & health policy

Nathalie Largeron, Pierre Lévy, Jürgen Wasem, Xavier Bresse

Affiliations

  1. Sanofi Pasteur MSD, Lyon, France.
  2. LEDa-LEGOS, Université Paris-Dauphine, Paris, France.
  3. Institute of Health Care Management and Research, Universität Duisburg, Essen, Germany.

PMID: 27123188 PMCID: PMC4802702 DOI: 10.3402/jmahp.v3.27043

Abstract

The use of vaccines to prevent diseases in children, adults, and the elderly results in fewer medical visits, diagnostic tests, treatments, and hospitalisations, which leads to substantial savings in healthcare costs each year in Europe and elsewhere. Vaccines also contribute to reducing resource utilisation by preventing nosocomial infections, such as rotavirus gastroenteritis, which can increase hospital stays by 4-12 days. Vaccination also has an important role in the prevention of cancers with, for example, human papillomavirus or hepatitis B vaccines. Since the financial impact of cancer is high for patients, healthcare systems, and society as a whole, any cases prevented will reduce this impact. Newer vaccines, such as the herpes zoster vaccine, can provide an answer to unmet medical needs by preventing and reducing the severity of shingles and associated post-herpetic neuralgia, which are difficult conditions to treat. Thus, in the context of increasing pressure on healthcare budgets, vaccination can contribute to the sustainability of healthcare systems through reduced and more efficient use of healthcare resources.

Keywords: cancers; costs; healthcare resource use; nosocomial infections; vaccination

References

  1. Lancet. 2000 Jan 8;355(9198):93-7 - PubMed
  2. BMJ. 2002 Apr 6;324(7341):809 - PubMed
  3. Pharmacoeconomics. 2004;22(13):839-55 - PubMed
  4. Pediatr Infect Dis J. 2006 Jan;25(1 Suppl):S12-21 - PubMed
  5. Pediatr Infect Dis J. 2006 Jan;25(1 Suppl):S7-S11 - PubMed
  6. Age Ageing. 2006 Mar;35(2):132-7 - PubMed
  7. Vaccine. 2006 May 8;24(19):4212-21 - PubMed
  8. Curr Med Res Opin. 2006 Apr;22(4):663-70 - PubMed
  9. Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18 - PubMed
  10. Gynecol Obstet Fertil. 2007 Feb;35(2):107-13 - PubMed
  11. Vaccine. 2007 May 16;25(20):3962-70 - PubMed
  12. J Infect Dis. 2007 May 1;195 Suppl 1:S36-S44 - PubMed
  13. Vaccine. 2007 Aug 21;25(34):6348-58 - PubMed
  14. BJOG. 2008 Jul;115(8):947-56 - PubMed
  15. BMC Infect Dis. 2010 Aug 09;10:235 - PubMed
  16. Rev Epidemiol Sante Publique. 2010 Dec;58(6):393-401 - PubMed
  17. Vaccine. 2011 Jul 18;29(32):5245-9 - PubMed
  18. Pharmacoeconomics. 2012 Jan;30(1):1-16 - PubMed
  19. Cancer Prev Res (Phila). 2012 Jan;5(1):24-9 - PubMed
  20. Vaccine. 2012 Mar 2;30(11):1993-8 - PubMed
  21. BMC Cancer. 2012 Jan 20;12:30 - PubMed
  22. Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):71-94 - PubMed
  23. BMC Infect Dis. 2012 Mar 19;12:62 - PubMed
  24. Int J Cancer. 2013 Mar 1;132(5):1133-45 - PubMed
  25. Vaccine. 2012 Dec 14;30(52):7443-6 - PubMed
  26. Clin Microbiol Infect. 2012 Dec;18 Suppl 6:5-12 - PubMed
  27. BMC Public Health. 2012 Nov 12;12:968 - PubMed
  28. Therapie. 2012 Sep-Oct;67(5):471-6 - PubMed
  29. Vaccine. 2013 Feb 4;31(7):1117-22 - PubMed
  30. Acta Paediatr. 2013 Apr;102(4):e158-63 - PubMed
  31. J Med Econ. 2013;16(6):763-76 - PubMed
  32. BMJ. 2013 Apr 18;346:f2032 - PubMed
  33. Expert Rev Vaccines. 2013 Sep;12(9):1085-94 - PubMed
  34. Int J Cancer. 2014 May 1;134(9):2264-8 - PubMed
  35. Vaccine. 2013 Nov 22;31 Suppl 8:I1-31 - PubMed
  36. MMWR Morb Mortal Wkly Rep. 2014 Apr 25;63(16):352-5 - PubMed
  37. BMC Public Health. 2014 Aug 07;14:813 - PubMed
  38. Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):913-27 - PubMed
  39. Expert Rev Vaccines. 2014 Nov;13(11):1279-90 - PubMed
  40. BMJ. 2015 Jan 06;350:g7584 - PubMed
  41. BMC Public Health. 2015 Feb 27;15:193 - PubMed
  42. J Prim Prev. 2015 Aug;36(4):259-73 - PubMed
  43. J Mark Access Health Policy. 2015 Aug 12;3:null - PubMed
  44. J Mark Access Health Policy. 2015 Aug 12;3:null - PubMed
  45. J Mark Access Health Policy. 2015 Aug 12;3:null - PubMed

Publication Types